Maxxim Medical
This article was originally published in The Gray Sheet
Executive Summary
Extends to Nov. 10 the expiration of its offer to purchase for cash any and all of the $100 mil. aggregate principal amount of its outstanding 10-1/2% senior subordinated notes due 2006. Holders of over $99.9 mil. of the notes had tendered their notes and delivered consents to amendments prior to the consent expiration date. Previously scheduled to expire on Oct. 29, the tender offer was launched in connection with Maxxim's previously announced proposal to merge with Fox Paine Medic Acquisition Corporation and recapitalize the company (1"The Gray Sheet" June 21, p. 19). The merger is expected to close in "mid-November," Maxxim says
You may also be interested in...
Maxxim Medical Management-Led Leveraged Buyout Valued At $800 Mil.
The management of Maxxim Medical plans to take the specialty medical products company private with the help of Foster City, California-based investment firm Fox Paine & Company and Chase Manhattan.
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.